



VIII CONGRESSO NAZIONALE ECOCARDIOCHIRURGIA 2016


Insufficienza mitralica ischemica: cardiochirurgia?

Carlo de Vincentiis




I.R.C.C.S. POLICLINICO SAN DONATO

Vicious circle



PROGNOSTIC IMPACT of IMV REGURGITATION

Medical history




REGURGITATION
↓ Leaves the pts
at risk of

FURTHER VOLUME
OVERLOAD

↓
PROGRESSIVE
REMODELING

PROGNOSTIC IMPACT of IMV REGURGITATION



Medical history



SURVIVAL is
INFLUENCED by
SEVERITY of
REGURGITATION

Also MODERATE
INSUFFICIENCY
REDUCES the
SURVIVAL

Functional MR and incidence of CHF in NYHA I-II pts



2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines



Class I

Patients undergoing CABG who have severe ischemic mitral valve regurgitation not likely to resolve with revascularization should have concomitant mitral valve repair or replacement at the time of CABG.^{489–492} (Level of Evidence: B)

Class IIa


In patients undergoing CABG who have moderate ischemic mitral valve regurgitation not likely to resolve with revascularization, concomitant mitral valve repair or replacement at the time of CABG is reasonable.^{489–492} (Level of Evidence: B)

2014 ESC/EACTS Guidelines on myocardial revascularization



Mitral valve surgery is indicated in patients with severe mitral regurgitation undergoing CABG, and LVEF >30%.	I	C
Mitral valve surgery should be considered in patients with moderate mitral regurgitation undergoing CABG to improve symptoms.	IIa	B
Repair of moderate-to-severe mitral regurgitation should be considered in patients with a primary indication for CABG and LVEF ≤ 35%.	IIa	B
Stress testing should be considered in patients with a primary indication for CABG and moderate mitral regurgitation to determine the extent of ischaemia and regurgitation.	IIa	C

MULTIPLE CAUSES of MITRAL ISCHEMIC REGURGITATION



TETHERING

LV
REMODELING

ISCHEMIA

ANNULAR DILATATION

REDUCTION of
CLOSING FORCE

Papillary muscle
rupture

MVR in
CAD



ANATOMICAL
Prolapse


ISCHEMIC

Papillary muscle
rupture


Natural History
↑Mortality at 3-4 days

Urgent Surgery

Type II



VALVE REPLACEMENT



- 15-25 % operative mortality
- Replacement 90% of cases

Surgical management of acute mitral valve regurgitation due to post infarction papillary muscle rupture

Tavakoli R – J Heart Valve Dis. 2002

Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation

Chevalier P - EICTS 2004

Mitral valve surgery for acute papillary muscle rupture following myocardial infarction

Chen Q – J Heart Valve Dis. 2002

IMVR


Severe

Moderate

CABG + MV surgery

CABG ONLY ?

CABG + MV surgery ?



*Moderate mitral regurgitation may progress
In 30-70% of patients who undergo surgical
revascularization alone*

Malidi HR - J Thorac Cardiovasc Surg 2004
Lam BK - Ann Thorac Surg 2005
Peniccka M - Circulation 2009
Fattouch K - Ann Thorac Surg 2010

IMVR

CABG + MV surgery vs *CABG alone*



- + reduction LVEDV
- Mitral regurgitation volume
- B-type natriuretic peptide levels
- + post-op NHYA
- LV dimension

Chan KM - Circulation 2012

Fattouch K - J. Thorac Cardiovasc Surg 2009


Ischemic mitral regurgitation : Surgery ?

YES

BPAC + Mitral Surgery


Undersized annuloplasty in IMR

- Feasible with low hospital mortality





- Improved symptoms and QOL

Second-order chordal cutting




hockey stick configuration

PM approximation




Relocation of the posterior PM



Mitral Valve Repair in Functional Ischemic Regurgitation

The 10-, 20-, and 30-year survivals
of 44%, 4%, and 0%, respectively
Whereas the freedom from MV
reoperation was only 63% at 10 years.



Cohn et al, J Thorac Cardiovasc Surg 2010

*" Mitral regurgitation may occur in 28% of
individuals 6 months following mitral repair "*

McGee et al J Thorac Cardiovasc Surg 2004

?

Severity of regurgitation

?

?

LV volume

left ventricular function

?

?

LV remodeling

?



Age

?

symptoms

?

Recurrence of Ischemic Mitral Regurgitation

Not performed Undersized annuloplasty

Bax and Braun : Unlikely LV reverse remodeling
if preoperative LVEDD exceeds 65 mm
and/or LVESD exceeds 51mm



- R. Dion : if the short axis is > 64 mm
something should be done on
the ventricle

- A. Calafiore : if the deep of the tenting
area is > 10 mm the valve
should be replaced


The presence of preoperative predictor of increased risk of mitral regurgitation recurrence and preoperative severity of regurgitation may indicate the correct surgical options

Severity	Treatment
Mild (grade 1+)	CABG
Moderate (grade 2+)	CABG vs CABG + down-sized mitral valve ring annuloplasty
Moderate-to-severe (grade 3) Severe (grade 4+)	CABG+down-sized mitral valve ring annuloplasty ± adjunct procedure vs CABG+mitral valve replacement

MVrepair vs MVreplacement



Lorusso et al :J. Thorac Cardiovasc Surgery 2013



Chan V. et al: Ann Thorac Surg 2011





FIGURE 2. Survival results for propensity-matched patients. There were no differences between patients undergoing MVR or MVP. Survival was comparable between propensity-matched groups of patients ($P = .72$). *MV*, Mitral valve.

Maltais et al :J. Thorac Cardiovasc Surgery 2011

MVrepair vs MVreplacement

randomized




Acker M. et al: N Engl J Med 2014

Both surgical approaches reduced left ventricular end-systolic volume index (LVESVI) at 12 months.

1-year mortality was similar in both groups

Regurgitation recurrence




Is repair preferable to replacement for ischemic mitral regurgitation?


A. Marc Gillinov, MD^a
Per Nils Wierup, MD^{a*}
Eugene H. Blackstone, MD^{a,b}
Ehab S. Bishay, MD^a
Delos M. Cosgrove, MD^a
Jennifer White, MS^b
Bruce W. Lytle, MD^a
Patrick M. McCarthy, MD^b

SI

NO



A




B


BETTER RISK pts

POOR RISK pts

Functional IMR with annular dilatation, LV remodeling, papillary muscle displacement



(C) Infarct Plication



Ramadan : JTCS 2005


Anterior leaflet augmentation (pericardial patch)	25	25	25
Percutaneous transvenous mitral annuloplasty (PTMA)	5 ^j	n.a.	n.a.
Percutaneous transvenous Alfieri edge-to-edge repair	1	n.a.	n.a.
Subvalvular techniques			
Second-order chordal cutting	43	43	40
Relocation of the PMPM (string)	18	18	18
Relocation of the PMPM (transventricular string)	12	12	12
PM sling	10	10	10
PM approximation	8	8	8
Ventricular techniques			
PM repositioning by infarct plication	3	0	3
Ventricular restoration and PM imbrication	46	0	46
Ventricular restoration			
External ventricular restraint device (epicardial balloon)	10 ^k	0	0
Coapsys device	11	0	11

Journal of Cardio-thoracic Surgery 37 (2010) 170–185

Techniques for CIMR.


MVA (n=)	CABG (n=)	Preoperative MR grade ^a	Follow-up (D)	Mortality at follow-up	MR grade at follow-up ^b
n.a.	290				
n.a.	554				
n.a.	4				
n.a.	37				
n.a.	5				
127	121				
25	25				
n.a.	n.a.				
n.a.	n.a.				
<p>Displacement of PM</p> <p>Reposition of PM</p>					
<p>≥ Grossi : JTCS 2006</p> <p>Mishra : Ann Thorac Surg 2006</p>					
2+ / 3+	7-14 months	38%	≤1+		
3+	7 months ^h	0%	0		
≥2+	Early postop	15%	≤1+ (84%), 2+ (13%), 4+ (3%)		
2.9 ± 1.2 ^e	Early postop	17%	0.7 ± 0.7 ^e		
7.8 ± 3.1 ^{e, l}	Intra-operative	0%	0.9 ± 0.8 ^{e, l}		
2.9 ± 0.5 ^e	1 year	0%	1.1 ± 0.8 ^e		

Coapsys devices




BEST SOLUTION

The disease process



PROBABLY

LEFT VENTRICULAR RESTORATION




Surgical ventricular restoration plus mitral valve repair

626 patients underwent SVR


175 (28%) had an additional MV repair

Operative death occurred in 14.3%




The actuarial survival at 3, 5 and 8 years was 72 ± 4 , 65 ± 4 and $45 \pm 6\%$, respectively

“Ischemic mitral regurgitation remains one of the most complex and unresolved aspect in the management of ischemic heart disease”



Mitral valve surgery after previous coronary artery bypass grafting

- Operative risk !
- Fe
- Age
- NYHA Class
- Urgent



In-hospital mortality 8.8%


Conclusion

- Ischemic Mitral regurgitation is a post IMA disease
- Must be differentiated from a MI determined by a transient ischemia
- Assessment of mitral valve before PTCA !
- Ischemia must be treated
- Mitral regurgitation must be treated

Conclusion

- Moderate IM Undersized annuloplasty probably is enough
- Annular surgery effective if EDD < 65 mm
- Replace the valve is not a “crime”!
- In Very large LV if the post-op LVEDD is expected to be more than 65 mm (in spite of SVR), replacement must be an option.

Ischemic Mitral Regurgitation



Thanks for your attention